Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Hypophosphatemia Associated With Injectafer Compared To Another Intravenous Anemia Drug

February 14, 2020 By Law Offices of Thomas J. Lamb, P.A.

A February 2020 article published by the JAMA medical journal, “Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia — Two Randomized Clinical Trials”, reports on the rate of hypophosphatemia associated with Injectafer compared to another intravenous iron deficiency anemia drug called Monoferric. This new Injectafer drug safety information concerning patients who develop hypophosphatemia following Injectafer treatments. when summarized as follows, is rather alerting:

  1. The hypophosphatemia incidence rate with Injectafer was 75% compared to 7.9% for Monoferric in the first trial; and,
  2. The hypophosphatemia incidence rate with Injectafer was 73.7% compared to 8.1 % for Monoferric in the second trial.

If a patient getting an Injectafer treatment develops Severe Hypophosphatemia (Severe HPP) they might thereafter be diagnosed with one of the following medical complications:

  • Osteomalacia
  • Arrhythmias
  • Cardiac Arrest
  • Respiratory Failure
  • Rhabdomyolysis

In this earlier post on our Drug Injury Watch blog, “Injectafer-Induced Hypophosphatemia Can Be A Serious Side Effect Of This Iron Deficiency Anemia Drug”, we considered how Injectafer (ferric carboxymaltose) can cause hypophosphatemia (HPP) as a side effect.

We are investigating possible drug injury lawsuits for patients who develop hypophosphatemia associated with Injectafer, i.e.,  hypophosphatemia following Injectafer treatments, and thereafter are diagnosed with a related medical complication.

[View article at original source]

Injectafer

Free Case Evaluation

Strictly Confidential, No Obligation

Filed Under: Unsafe Drugs Tagged With: arrhythmias, cardiac arrest, Hypophosphatemia, Injectafer, osteomalacia, respiratory failure, Rhabdomyolysis

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.